Pasi Janne
机构: Dana Farber Cancer Institute
每年引用次数
引用次数
引用: 134,728
H-指数: 163
I10-指数 : 547
出版物: 1,257
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.
Danie Paul , Abigail A. Santos , Pasi A. Jänne , Geoffrey R. Oxnard
Cancer 122 ( 22) 3456 -3463
9
2016
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Shirish M. Gadgeel , Fadlo R. Khuri , Jeff A. Engelman , Marianna Koczywas
Cancer 120 ( 8) 1145 -1154
160
2014
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer.
Adrian G. Sacher , Pasi A. Jänne , Geoffrey R. Oxnard
Cancer 120 ( 15) 2289 -2298
27
2014
Monitoring cancer through the blood
Cloud P. Paweletz , Pasi A. Jänne
Cancer 120 ( 24) 3859 -3861
2
2014
Abstract LB-88: Identification of recurrent oncogenic KIF5B-RET rearrangements in non-small cell lung cancer
Marzia Capelletti , Doron Lipson , Geoff Otto , Roman Yelensky
Cancer Research 72
2012
Gefitinib for Epidermal Growth Factor Receptor Mutant Lung Cancers: Searching for a Weapon of Mass Destruction
Pasi A. Jänne
Journal of Clinical Oncology 24 ( 21) 3319 -3321
6
2006
Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib
David M. Jackman , Alison J. Holmes , Neal Lindeman , Patrick Y. Wen
Journal of Clinical Oncology 24 ( 27) 4517 -4520
212
2006
Phase II Trial of Cetuximab in Patients With Previously Treated Non–Small-Cell Lung Cancer
Nasser Hanna , Rogerio Lilenbaum , Rafat Ansari , Thomas Lynch
Journal of Clinical Oncology 24 ( 33) 5253 -5258
168
2006
Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial
Federico Cappuzzo , Claudia Ligorio , Pasi A. Jänne , Luca Toschi
Journal of Clinical Oncology 25 ( 16) 2248 -2255
198
2007
Selecting Patients for Epidermal Growth Factor Receptor Inhibitor Treatment: A FISH Story or a Tale of Mutations?
Bruce E. Johnson , Pasi A. Jänne
Journal of Clinical Oncology 23 ( 28) 6813 -6816
52
2005
Meningeal Carcinomatosis in Lung Cancer
Pasi A. Jänne , Milos J. Janicek , Felix Brown
Journal of Clinical Oncology 18 ( 15) 2927 -2929
10
2000
Lung Cancer Presenting With Solitary Bone Metastases
Pasi A. Jänne , Milton W. Datta , Bruce E. Johnson
Journal of Clinical Oncology 17 ( 9) 2998 -3001
10
1999
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
Claudia Voena , Matteo Menotti , Cristina Mastini , Filomena Di Giacomo
Cancer immunology research 3 ( 12) 1333 -1343
23
2015
Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer
Mizuki Nishino , Emily S. Chambers , Curtis R. Chong , Nikhil H. Ramaiya
Cancer immunology research 4 ( 4) 289 -293
84
2016
Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
Mark M. Awad , Robert E. Jones , Hongye Liu , Patrick H. Lizotte
Cancer immunology research 4 ( 12) 1038 -1048
40
2016
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
Patrick H. Lizotte , Ruey-Long Hong , Troy A. Luster , Megan E. Cavanaugh
Cancer immunology research 6 ( 12) 1511 -1523
26
2018
Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines
Antonio Calles , Nicholas Kwiatkowski , Bernard K. Cammarata , Dalia Ercan
Molecular Oncology 9 ( 1) 260 -269
38
2015
Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations.
Jaebong Jang , Ciric To , Dries J. H. De Clercq , Eunyoung Park
Angewandte Chemie 59 ( 34) 14481 -14489
57
2020
New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy
Mizuki Nishino , David M. Jackman , Hiroto Hatabu , Beow Y. Yeap
American Journal of Roentgenology 195 ( 3) W221 -W228
140
2010
An unbiased in vitro screen for activating epidermal growth factor receptor mutations.
Deepankar Chakroborty , Kari J. Kurppa , Ilkka Paatero , Veera K. Ojala
Journal of Biological Chemistry 294 ( 24) 9377 -9389
13
2019